Diabetes is one of the
common chronic diseases.
As a country with a large population, affected by aging, dietary improvement and other factors, the number of diabetic patients in China has also risen
rapidly in recent years.
According to the International Diabetes Federation, the number of adult diabetics in China is gradually increasing, with about 140 million in 2021, an increase of about 21.
55%
over 2019.
The increasing number of diabetic patients is driving the growth
of the diabetes drug market.
According to data, the size of China's diabetes drug market reached 63.
2 billion yuan in 2020, and it is expected to reach 116.
1 billion yuan in 2025 and 167.
5 billion yuan
in 2030.
The huge domestic market space for hypoglycemic drugs is attracting the layout
of many domestic and foreign pharmaceutical companies.
On January 5, Hanyu Pharmaceutical issued an announcement that the company received the "Drug Registration Certificate" issued by the State Medical Products Administration, and the company's hypoglycemic drug "vildagliptin tablets" was approved for marketing and deemed to have passed the consistency evaluation
.
Vildagliptin is indicated for the treatment of type 2 diabetes
.
When diet and exercise can not effectively control blood sugar, this product can be used as monotherapy; When metformin as a monotherapy to the maximum tolerated dose can not effectively control blood sugar, this product can be combined with metformin; When a stable dose of insulin can not effectively control blood sugar, this product can be used in combination with insulin (with or without metformin); When a stable dose of sulfonylureas still cannot effectively control blood sugar, this product can be used
in combination with sulfonylureas.
The drug was developed by Novartis and approved for marketing in the European Union in 2007, and according to Minai.
com, Novartis' global sales of the product in 2019 were close to $1.
3 billion
.
In China, vildagliptin has entered the 2017 edition of the medical insurance catalog
.
In 2021, the sales of vildagliptin tablets in domestic sample hospitals (including urban public hospitals, urban community hospitals, county-level public hospitals, township health centers) and urban physical pharmacies were about RMB 150 million
.
In terms of consistency evaluation, among the domestic generic drug companies, in addition to Hanyu Pharmaceutical, there were also Haosen, Qilu, China Biopharmaceutical, Zhejiang Nuode Pharmaceutical, etc.
that were approved earlier, of which Haosen won the first place, and there were many pharmaceutical companies
in the review of the 4-class generic acceptance number of vildagliptin tablets.
It can be seen that the competition on the track is becoming more and more fierce, and domestic generic drug companies are accelerating the siege of Novartis
.
For the approval of vildagliptin tablets, Hanyu Pharmaceutical said that it will further enrich the company's product categories and expand the company's product layout
.
It is conducive to the company's market development in the field of diabetes and improves the company's market competitiveness
in the field of treatment.
The acquisition of the drug registration certificate will have a positive impact
on the company's future performance.
According to the data, Hanyu Pharmaceutical's main products include preparations, characteristic APIs, customized peptides, solid preparations, medical devices and other products
.
Hanyu Pharmaceutical once said on the investor interactive platform that the company has focused on peptide drugs for more than 20 years and has completed the product layout of peptide drugs in the therapeutic fields of obstetrics and gynecology assisted reproduction, diabetes, digestive tract diseases, cardiovascular diseases and so on; The future innovation direction of peptide drugs also includes tumor/immune system, antiviral, anti-infection, vaccine, central nervous system, metabolism and other emerging therapeutic and prevention fields
.
According to the 2021 annual report, Hanyu Pharmaceutical achieved operating income of 736 million yuan, a year-on-year increase of 1.
97%, and a net profit attributable to the parent of about 30.
808 million, a year-on-year increase of 105.
06%.
In the first three quarters of 2022, the company achieved a total operating income of 531 million yuan, a year-on-year increase of 4.
6%; The net profit attributable to the parent was -147 million yuan, compared with -120 million yuan in the same period last year, and the loss range widened
.
As of the close on January 5, Hanyu Pharmaceutical closed at 18.
67 yuan, up 2.
41%, with a turnover rate of 8.
55%, a volume of 598,500 lots and a turnover of 1.
105 billion yuan
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
